Scholarlink

<p>ACP-105 (CAS: 1048998-11-3) is a novel non-steroidal selective androgen receptor modulator (SARM), increasingly detected in anti-doping analyses, yet lacking a comprehensive ADME profile. This study provides the first integrative in silico characterization of ACP-105’s ADME properties using seven independent methods (ADMETlab 3.0, ADMET Predictor 12.0, ACD/Percepta, SwissADME, pkCSM, XenoSite and DruMAP). The compound demonstrated high gastrointestinal absorption (up to 100%), moderate lipophilicity (LogP 3.0–3.52), low solubility (LogS ~ −&#xa0;4.1 to −&#xa0;4.4), and Caco-2 permeability ranging from 13.6 to 152 × 10<sup>−6</sup>&#xa0;cm/s. It shows strong plasma protein binding (77–99%), minimal free plasma fraction (&lt; 1%), and variable tissue distribution (Vd 0.18–12&#xa0;L/kg). Blood–brain barrier penetration was predicted in most models. Metabolic profiling identified six metabolites (M1–M6), primarily formed via CYP3A4, with additional contributions from CYP2C9, CYP2C19, and CYP2D6. ACP-105 is a consistent substrate for CYP3A4 (82–100%) and likely undergoes stable and unstable oxygenation, N-dealkylation, and UGT conjugation. Interactions with DNA/protein and potential cyanide release were also predicted. Clearance predictions varied (7.175–3.86 × 10<sup>−5</sup>&#xa0;mL/min/kg), with a short half-life (~ 1.18&#xa0;h), and no OCT2-mediated renal excretion expected. These findings provide a foundational ADME profile of ACP-105, essential for interpreting exposure in clinical toxicology and supporting evidence in forensic investigations involving illicit use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First multifaceted ADME profile of ACP-105 (CAS: 1048998-11-3): a novel non-steroidal selective androgen receptor modulator used as doping in sports—integrative in silico toxicological studies for clinical and forensic toxicology purposes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月10日

查看全文
  • Oktawia Fijałkowska,
  • Kamil Jurowski

摘要

ACP-105 (CAS: 1048998-11-3) is a novel non-steroidal selective androgen receptor modulator (SARM), increasingly detected in anti-doping analyses, yet lacking a comprehensive ADME profile. This study provides the first integrative in silico characterization of ACP-105’s ADME properties using seven independent methods (ADMETlab 3.0, ADMET Predictor 12.0, ACD/Percepta, SwissADME, pkCSM, XenoSite and DruMAP). The compound demonstrated high gastrointestinal absorption (up to 100%), moderate lipophilicity (LogP 3.0–3.52), low solubility (LogS ~ − 4.1 to − 4.4), and Caco-2 permeability ranging from 13.6 to 152 × 10−6 cm/s. It shows strong plasma protein binding (77–99%), minimal free plasma fraction (< 1%), and variable tissue distribution (Vd 0.18–12 L/kg). Blood–brain barrier penetration was predicted in most models. Metabolic profiling identified six metabolites (M1–M6), primarily formed via CYP3A4, with additional contributions from CYP2C9, CYP2C19, and CYP2D6. ACP-105 is a consistent substrate for CYP3A4 (82–100%) and likely undergoes stable and unstable oxygenation, N-dealkylation, and UGT conjugation. Interactions with DNA/protein and potential cyanide release were also predicted. Clearance predictions varied (7.175–3.86 × 10−5 mL/min/kg), with a short half-life (~ 1.18 h), and no OCT2-mediated renal excretion expected. These findings provide a foundational ADME profile of ACP-105, essential for interpreting exposure in clinical toxicology and supporting evidence in forensic investigations involving illicit use.